登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

Core Viewpoint - The company reported a decline in net profit for the first quarter of 2025, primarily due to changes in the VAT calculation method for in vitro diagnostic reagents, leading to a decrease in operating revenue compared to the same period last year [4][5][6]. Financial Data Summary - The first quarter financial report is unaudited [3]. - The company's net profit decreased compared to the same period last year, attributed to the adjustment of the VAT calculation method for in vitro diagnostic reagents, resulting in a decline in operating revenue [4]. - The net cash flow from operating activities decreased by 134.97% compared to the same period last year, mainly due to reduced accounts receivable collections from the subsidiary [4]. Shareholder Information - As of the end of the reporting period, the company held 1,291,428 shares in its repurchase account, accounting for 3.23% of the total share capital [6]. Board Meeting Resolutions - The company held its 11th meeting of the second board on April 28, 2025, where several resolutions were passed, including the approval of the 2024 annual general manager's work report and the 2024 annual board work report [9][11]. - The board also approved the 2024 financial settlement report and the 2024 annual report, which will be submitted for shareholder approval [13][16]. Profit Distribution Plan - The company proposed a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distribution amounting to 3,870,857.20 yuan based on the adjusted total shares [99][100]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [101][103]. Related Transactions - The company plans to use idle funds to purchase financial products from Jiangnan Rural Commercial Bank, with a maximum balance of 50 million yuan and a term not exceeding 12 months [63][64]. - This transaction has been approved by the board and will be submitted for shareholder approval [79][80]. Audit Firm Appointment - The company intends to reappoint Lixin Certified Public Accountants as its auditor for the 2025 fiscal year, pending shareholder approval [86][87]. - Lixin has a strong track record and has provided audit services to numerous listed companies [88][89].

Core Viewpoint - The company reported a steady recovery in its business operations during the first quarter of 2025, with a year-on-year revenue growth of 0.54% and a quarter-on-quarter growth of 12.37% despite external pressures [3]. Financial Performance - The company achieved operating revenue of 0.92 billion yuan in the first quarter of 2025, reflecting a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37% [3]. - The overseas market showed significant growth, with overseas revenue increasing by 69.00% year-on-year due to prior product certifications and strategic deployment [3]. - The net profit declined due to price pressures from centralized procurement in the in vitro diagnostics industry, a VAT adjustment on self-produced testing reagents to 13%, and a reduction in government subsidies [3]. Asset Impairment - The company conducted impairment testing on its assets as of March 31, 2025, and recognized a total impairment provision of 59.06 thousand yuan, which included 18.64 thousand yuan for expected credit losses and 40.42 thousand yuan for inventory write-downs [13][14]. - The impairment provisions are expected to increase the company's profit before tax by 318.29 thousand yuan for the first quarter of 2025 [14]. Governance and Compliance - The board of directors and the supervisory board confirmed the accuracy and completeness of the quarterly report, ensuring compliance with relevant laws and regulations [2][8]. - The supervisory board reviewed and approved the first quarter report, affirming that it reflects the company's financial status and operational results accurately [8][9].

2024年，公司及子公司在不影响公司正常经营资金需求和确保资金安全的前提下，使用部分暂时闲置的 自有资金进行委托理财，总额度不超过10亿元。截至2024年12月31日，未到期理财余额为5.13亿元。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 2024年度证券投资情况的专项说明》。 （十）《智度科技股份有限公司2025年度董事薪酬方案》 因该事项与全体董事存在利害关系，因此全体董事回避表决，本议案将直接提交公司股东会审议。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司2025年 度董事、监事及高级管理人员薪酬方案》。 登录新浪财经APP 搜索【信披】查看更多考评等级 （九）《智度科技股份有限公司关于2024年度证券投资情况的专项说明》 表决结果：五票同意、零票反对、零票弃权。本议案获得通过。 表决结果：三票同意、零票反对、零票弃权。本议案获得通过。 关联董事陆宏达先生和刘广飞先生回避表决。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 ...

Group 1 - The company announced the introduction of strategic investors for its wholly-owned subsidiary, Jiangxi Taihao Military Industry Group Co., Ltd., with a total capital increase of 798.2851 million yuan [2][4] - After the capital increase, the strategic investors will hold a total of 27.88% equity in Taihao Military Industry, which will remain a controlled subsidiary of the company [2][4] - The strategic investors include Beijing Guofa Aviation Engine Industry Investment Fund Center, Yulin Coal Resource Transformation Guidance Fund, Chongqing Taihefeng Private Equity Investment Fund, among others [2][4] Group 2 - The company is currently advancing the process of acquiring a total of 27.46% equity in Taihao Military Industry through the issuance of shares [4] - Recent agreements have been signed to amend the original investment agreements, terminating certain special rights previously held by the investors, such as the "repurchase right" [4][6] - The new agreements will take effect upon signing and will have the same legal effect as the original agreements, with certain clauses being suspended until the transaction is approved by the Shanghai Stock Exchange [6][7] Group 3 - The company reported a total asset impairment provision of 536,436,183.54 yuan for the year 2024, which will reduce the pre-tax profit for the consolidated financial statements [10][19] - The company also wrote off assets totaling 48,957,739.60 yuan, which will increase the pre-tax profit for the consolidated financial statements by 2,858,445.79 yuan [10][19] - The overall impact of the asset impairment and write-off will result in a net reduction of 533,577,737.75 yuan in the pre-tax profit for the year 2024 [19] Group 4 - The company reported a net loss of 991,034,446.51 yuan for the year 2024, leading to an unremedied loss amounting to one-third of the paid-in capital [22][23] - The primary reasons for the loss include delays in military projects and a decline in profitability for its subsidiary, Shanghai Hongsheng System Engineering Co., Ltd., due to intensified industry competition [23] - The company plans to accelerate military project progress, enhance market expansion in the emergency power supply sector, increase R&D investment, and continue to divest inefficient assets [23][24] Group 5 - The company plans to apply for a total comprehensive credit limit of up to 7.29 billion yuan for the year 2025, with a guarantee amount not exceeding 2.49 billion yuan for its subsidiaries [38][39] - The credit limit will be valid from the date of approval by the 2024 annual general meeting until the 2025 annual general meeting [38][39] - The company has no overdue guarantees and is within the authorized guarantee limit approved by the shareholders [41][56] Group 6 - The company intends to renew its contract with Da Xin Accounting Firm for the 2025 financial audit and internal control audit [60] - Da Xin Accounting Firm has extensive experience in securities services and has provided audit services to over 10,000 companies [62] - The renewal of the accounting firm is subject to approval at the upcoming shareholders' meeting [60][62]

Group 1 - The company has recognized an asset impairment provision of 138,394.48 million yuan for the year 2024, which will reduce the total profit by the same amount and decrease the net profit attributable to shareholders by 129,726.17 million yuan [1] - The board of directors believes that the standards and basis for the impairment provision are reasonable and sufficient, complying with relevant accounting standards, and that the financial information will objectively reflect the company's asset status [1] Group 2 - The company held its 12th board meeting on April 25, 2025, with all six directors present, and the meeting was deemed valid [4][5] - The board approved several reports including the 2024 annual report and the financial settlement report, all of which will be submitted to the 2024 annual general meeting for further approval [10][12][54] Group 3 - The company plans to provide guarantees for its subsidiaries, with a total guarantee amount not exceeding 60 billion yuan for the year 2025, divided into 40 billion yuan for subsidiaries with a debt-to-asset ratio above 70% and 20 billion yuan for those below [58] - The board has approved the guarantee plan, which will be submitted to the shareholders' meeting for approval [59]

登录新浪财经APP 搜索【信披】查看更多考评等级 三、会议登记事项 1、登记方式：现场登记、书面信函或传真方式登记。 （1）自然人股东登记：自然人股东须持本人身份证（原件）、证券账户卡（复印件）办理登记手续； 委托代理人出席的应持代理人身份证（原件）、授权委托书（原件，见附件1）、委托人身份证（复印 件）和委托人证券账户卡（复印件）办理登记手续； （2）法人股东登记：法人股东由法定代表人出席会议的，须持本人身份证（原件）、营业执照（复印 件加盖公章）、法定代表人身份证明书（原件）和证券账户卡（复印件）办理登记手续；由法定代表人 委托的代理人出席会议的，持代理人身份证（原件）、法定代表人身份证（复印件）、营业执照（复印 件加盖公章）、法定代表人身份证明书（原件）、授权委托书（原件，法定代表人签署并加盖公章，见 附件1）和证券账户卡（复印件）办理登记手续； （3）异地股东可以凭上述文件以书面信函或传真方式办理登记。 拟出席本次会议的股东应将上述材料及股东大会参会股东登记表（见附件2）以专人送达、信函或传真 方式送达本公司。 2、登记时间： （1）现场登记时间：2025年5月15日（星期四）上午9:00-11:30 ...

2024年中喜会计师事务所购买的职业保险累计赔偿限额10,000.00万元，能够覆盖因审计失败导致的民事 赔偿责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 3、诚信记录 中喜所未受到刑事处罚。 中喜所近三年执业行为受到监督管理措施5次，21名从业人员近三年因执业行为受到监督管理措施共11 次。 中喜所近三年执业行为受到行政处罚1次，2名从业人员近三年因执业行为受到行政处罚共1次。 中喜所近三年执业行为受到纪律处分1次，2名从业人员近三年因执业行为受到纪律处分共1次。 （二）项目信息 1、中喜会计师事务所（特殊普通合伙）及其从业人员不存在违反《中国注册会计师职业道德守则》对 独立性要求的情形。项目组成员具备相应的专业胜任能力，主要成员信息如下： （1）项目合伙人：蒋建友，中国注册会计师，2002年注册，长期从事审计及与资本市场相关的专业服 务工作，具备相应专业胜任能力。 （2）拟任签字注册会计师：欧阳静波，中国注册会计师，2009年注册，长期从事审计及与资本市场相 关的专业服务工作，具备相应的专业胜任能力。 （3）项目质量控制复核人：黄颖君，中国注册会计师，2009年注册，长期从事审计及与资本市场相 ...

Group 1 - The company held its 33rd meeting of the 8th Board of Directors on April 25, 2025, with all 7 directors present, and the meeting complied with the Company Law and the company's articles of association [2][3] - The Board approved the 2024 Annual Work Report, which will be submitted to the shareholders' meeting for review [3][4] - The Board also approved the 2024 Annual Report and its summary, which covers governance, operations, financial status, and internal controls [7][8] Group 2 - The company plans not to distribute profits for 2024 due to a negative net profit, aiming to protect the long-term interests of shareholders [10][60] - The Board approved the 2024 Financial Settlement Report, which has been audited and received a standard unqualified opinion [8][9] - The company reported an unallocated loss of approximately 1.49 billion yuan, exceeding one-third of the paid-in capital [13] Group 3 - The company approved the 2024 Internal Control Evaluation Report, indicating a robust governance structure and effective internal controls [16][63] - The company also approved the 2024 Social Responsibility Report and ESG Report, reflecting its commitment to environmental, social, and governance standards [23][65] - The Board approved changes to accounting policies and the provision for asset impairment, ensuring accurate financial reporting [27][30][67] Group 4 - The company plans to cancel the Supervisory Board and amend its articles of association to enhance governance [43][75] - The company approved the 2025 First Quarter Report, which has not been audited [78][82] - The company has set a guarantee limit of up to 17 billion yuan for 2025 for its subsidiaries, with a current usage of approximately 8.95 billion yuan [87][89]

Fundraising Overview - The company raised a total of RMB 960,863,346.06 from the public offering of 25,166,667 shares at a price of RMB 38.18 per share, with a net amount of RMB 864,084,244.88 after deducting issuance costs [1][2] - The funds are managed under a dedicated account storage system to ensure proper usage and investor protection [1][2] Fund Usage and Management - As of December 31, 2024, the company has invested RMB 29,300.12 million from the raised funds into relevant projects [3] - The company has signed tripartite and quadripartite agreements with various banks and sponsors to clarify the rights and obligations regarding the management of the raised funds [2] Pre-investment and Reimbursement - The company pre-invested RMB 101,680,802.59 using self-raised funds for projects and issuance costs, with RMB 97,591,022.71 eligible for reimbursement from the raised funds [3] - The board approved the use of raised funds to reimburse the pre-invested amounts, ensuring efficient fund utilization [3] Idle Fund Management - The company did not use idle raised funds to temporarily supplement working capital in 2024 [4] - A resolution was passed to manage temporarily idle funds and excess raised funds through cash management products, with a total amount not exceeding RMB 600 million [5][6] Fund Allocation and Adjustments - The company has not made any changes to the fundraising investment projects as of December 31, 2024 [9] - The company approved the addition of a subsidiary as the implementation entity for certain projects and established a dedicated account for managing the related funds [8] Compliance and Reporting - The company has complied with relevant laws and regulations regarding the use and management of raised funds, with no violations reported [10] - The accounting firm provided a verification report confirming that the fundraising activities were conducted in accordance with regulatory requirements [10][11]